Association of elevated blood levels of pentachlorophenol (PCP) with cellular and humoral immunodeficiencies

Citation
V. Daniel et al., Association of elevated blood levels of pentachlorophenol (PCP) with cellular and humoral immunodeficiencies, ARCH ENV HE, 56(1), 2001, pp. 77-83
Citations number
39
Categorie Soggetti
Environment/Ecology,"Pharmacology & Toxicology
Journal title
ARCHIVES OF ENVIRONMENTAL HEALTH
ISSN journal
00039896 → ACNP
Volume
56
Issue
1
Year of publication
2001
Pages
77 - 83
Database
ISI
SICI code
0003-9896(200101/02)56:1<77:AOEBLO>2.0.ZU;2-Y
Abstract
It has long been suspected that pentachlorophenol (PCP) exerts a damaging i nfluence on the immune system. In this study, the possible relationship bet ween blood levels of PCP and immune function was studied in 190 patients wh o had been exposed for move than 6 mo to PCP-containing pesticides. The pat ients suffered from frequent respiratory infections and general fatigue. Ly mphocyte subpopulations, in-vitro responses to mitogens, allogeneic stimula tor cells, plasma neopterin, cytokines, soluble cytokine receptors, soluble adhesion molecules, and immunoglobulin autoantibodies were determined. A d ose-response relationship between blood levels of PCP and cellular and humo ral immune parameters was established. Blood levels of PCP were associated negatively with (a) total lymphocyte counts (p =.0002), CD4/CD8 ratios (p = .0015), and absolute counts of CD3+ (p <.0001), CD4+ (p <.0001), CD16+ (p < .0001), CD25+ (p.0003), DR+ (p <.0001), CD8+/56+ (p =.020), and CD19+ cells (p =.092); (b) plasma levels of interleukin-2 (IL-2) (p <.0001), soluble l L-2R (p <.0001), IL-6 (p <.0001), IL-10 (p =.0039), interferon-gamma (IFN-< gamma>) (p <.0001), tumor necrosis factor-alpha (TNF-<alpha>) (p <.0001), t ransforming-growth factor-beta(2) (p =.023), soluble IL-1 receptor antagoni st (slL-1RA) (p <.0001), soluble intercellular adhesion molecule-1 (p =.000 3); and (c) immunoglobulin (Ig) M-anti-Fab type autoantibodies (p =.0353). PCP levels were associated positively with (a) number of impaired stimulati on assays per patient (p =.041); (b) number of circulating CD11b+ monocytes (p =.0015); and (c) plasma levels of neopterin (p <.0001), IL-4 (p =.020), and sIL-6R (p =.020). Compared with patients who had PCP plasma levels tha t were less than or equal to 10 <mu>g/l, patients with brood levels of PCP that exceeded 10 mug/l experienced the following more often: low numbers of total blood lymphocytes (p.054), CD3+ (p =.0014), CD4+ (p =.0001), DR+ (p =.0003), CD16+ (p.0033), and CD25+ cells (p =.0033). In addition, the same aforementioned patients experienced the following more frequently: undetect able plasma levels of IL-2 (p =.0057), IL-6 (p =.042), IL-8 (p =.038), IL-1 0 (p.0001), TNF-a (p =.0062), and IFN-gamma (p =.016); and impaired in-vitr o responses of lymphocytes (p=.071). The authors concluded that increased b lood levels of PCP were associated significantly with cellular and humoral immunodeficiencies. Recurrent respiratory infections and general fatigue co uld originate from PCP-associated immunosuppression.